MIDATECH PHARMA PLC-ADR (MTP) Stock Price, Forecast & Analysis
NASDAQ:MTP • US59564R5000
MTP Key Statistics, Chart & Performance
The current stock price of MTP is 0.2851 USD. In the past month the price decreased by -47.19%. In the past year, price decreased by -93.38%.
MTP Technical Analysis
MTP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MTP. MTP may be in some trouble as it scores bad on both profitability and health.
MTP Financial Highlights
Over the last trailing twelve months MTP reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS increased by 58.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.07 |
MTP Forecast & Estimates
MTP Ownership
MTP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.66 | 397.113B | ||
| AMGN | AMGEN INC | 17.16 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.46 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.07 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.86 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.36 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.57 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.98 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MTP
Company Profile
Midatech Pharma Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 20 full-time employees. The company went IPO on 2014-12-08. The firm is focused on improving the bio-delivery and biodistribution of medicines. The firm's technologies include Q-Sphera, MidaSolve and MidaCore. Q-Sphera technology focusses on long acting injectables using three-dimensional (3D) printing technology. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. The company has a pipeline of approximately 10 earlier stage programmes, which includes MTD211 (Schizophrenia, MDD), MTD219 (Prophylaxis, transplant rejection), MTX223, MTX213, MTX214, MTX110 (Glioblastoma), MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma) and MTX114 (Psoriasis).
Company Info
MIDATECH PHARMA PLC-ADR
Oddfellows Hse, 19 Newport Road
Abingdon OXFORDSHIRE CF24 0AA GB
CEO: Stephen Stamp
Employees: 20
Phone: 4401235888300.0
MIDATECH PHARMA PLC-ADR / MTP FAQ
Can you describe the business of MIDATECH PHARMA PLC-ADR?
Midatech Pharma Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 20 full-time employees. The company went IPO on 2014-12-08. The firm is focused on improving the bio-delivery and biodistribution of medicines. The firm's technologies include Q-Sphera, MidaSolve and MidaCore. Q-Sphera technology focusses on long acting injectables using three-dimensional (3D) printing technology. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. The company has a pipeline of approximately 10 earlier stage programmes, which includes MTD211 (Schizophrenia, MDD), MTD219 (Prophylaxis, transplant rejection), MTX223, MTX213, MTX214, MTX110 (Glioblastoma), MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma) and MTX114 (Psoriasis).
What is the current price of MTP stock?
The current stock price of MTP is 0.2851 USD. The price decreased by -18.52% in the last trading session.
Does MIDATECH PHARMA PLC-ADR pay dividends?
MTP does not pay a dividend.
What is the ChartMill technical and fundamental rating of MTP stock?
MTP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of MIDATECH PHARMA PLC-ADR (MTP)?
MIDATECH PHARMA PLC-ADR (MTP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.96).
What is the next earnings date for MTP stock?
MIDATECH PHARMA PLC-ADR (MTP) will report earnings on 2023-04-24.